Successful treatment of hepatocellular carcinoma with regorafenib after sorafenib-induced hypersensitivity

Naoki Yoshioka, Teiji Kuzuya, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Mitsuhiro Fujishiro

Research output: Contribution to journalArticlepeer-review

Abstract

Sorafenib and regorafenib are tyrosine kinase inhibitors that are used in the treatment of hepatocellular carcinoma and which have similar chemical structures and toxicity profiles. We herein report a case in which regorafenib treatment could be continued for 10 months and stable disease could be maintained for a long period despite the discontinuation of sorafenib due to grade 4 liver injury and grade 3 fever. The severe adverse events could be attributed to drug hypersensitivity, since a drug-induced lymphocyte stimulation test (DLST) indicated sensitivity to sorafenib. A DLST for regorafenib was negative. This is the first report showing that regorafenib could be safely administered after the discontinuation of sorafenib due to hypersensitivity.

Original languageEnglish
Pages (from-to)2803-2808
Number of pages6
JournalInternal Medicine
Volume58
Issue number19
DOIs
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint Dive into the research topics of 'Successful treatment of hepatocellular carcinoma with regorafenib after sorafenib-induced hypersensitivity'. Together they form a unique fingerprint.

Cite this